Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 OtonomyAdamis PharmaceuticalsAnixa BiosciencesMinerva NeurosciencesZynerba Pharmaceuticals
SymbolNASDAQ:OTICNASDAQ:ADMPNASDAQ:ANIXNASDAQ:NERVNASDAQ:ZYNE
Price Information
Current Price$2.33$0.75$4.31$2.57$4.19
52 Week RangeBuyHoldBuyBuyBuy
MarketRank™
Overall Score1.71.31.41.61.3
Analysis Score3.53.03.53.33.4
Community Score2.63.02.92.82.7
Dividend Score0.00.00.00.00.0
Ownership Score1.70.00.81.70.0
Earnings & Valuation Score0.60.60.00.00.6
Analyst Ratings
Consensus RecommendationBuyHoldBuyBuyBuy
Consensus Price Target$8.30$1.25$11.00$6.75$13.65
% Upside from Price Target256.22% upside66.18% upside155.22% upside162.65% upside225.78% upside
Trade Information
Market Cap$110.17 million$110.41 million$129.18 million$107.66 million$181.92 million
Beta2.311.681.581.492.83
Average Volume1,112,56116,703,836605,787587,6794,811,492
Sales & Book Value
Annual Revenue$600,000.00$22.11 million$250,000.00N/A$90,000.00
Price / Sales187.645.07541.87N/A1,920.51
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$1.31 per share$0.58 per share$0.35 per share$0.71 per share$3.26 per share
Price / Book1.781.3012.31N/A1.29
Profitability
Net Income$-44,670,000.00$-29,310,000.00$-10,020,000.00$-72,180,000.00$-32,940,000.00
EPS($1.45)($0.55)($0.59)($1.85)($1.50)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-14,379.87%-188.31%N/AN/AN/A
Return on Equity (ROE)-108.75%-99.57%-153.08%-51.19%-60.20%
Return on Assets (ROA)-54.62%-67.47%-129.89%-29.75%-52.40%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.20%0.05%N/AN/AN/A
Current Ratio8.97%1.32%7.88%6.49%6.54%
Quick Ratio8.97%1.16%7.88%6.49%6.54%
Ownership Information
Institutional Ownership Percentage72.25%7.36%7.68%66.28%25.99%
Insider Ownership Percentage16.10%5.90%23.30%12.00%11.10%
Miscellaneous
Employees5613131126
Shares Outstanding48.32 million148.89 million31.43 million42.72 million41.25 million
Next Earnings Date5/6/2021 (Estimated)5/17/2021 (Estimated)6/8/2021 (Estimated)5/3/2021 (Estimated)5/10/2021 (Estimated)
OptionableOptionableOptionableNot OptionableOptionableOptionable
SourceHeadline
Zynerba Pharmaceuticals Inc. [ZYNE] Stock trading around $4.41 per share: What’s Next?Zynerba Pharmaceuticals Inc. [ZYNE] Stock trading around $4.41 per share: What’s Next?
dbtnews.com - April 22 at 10:08 AM
Short Interest in Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Decreases By 23.7%Short Interest in Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Decreases By 23.7%
americanbankingnews.com - April 18 at 1:56 AM
Zynerba Pharmaceuticals Announces the Acceptance of Two Posters at the Society of Biological ...Zynerba Pharmaceuticals Announces the Acceptance of Two Posters at the Society of Biological ...
apnews.com - April 16 at 9:23 AM
Zynerba Pharmaceuticals Inc (ZYNE)Zynerba Pharmaceuticals Inc (ZYNE)
investing.com - April 15 at 1:39 PM
Zynerba Pharmaceuticals Announces the Acceptance of Two Posters at the Society of Biological Psychiatry 2021 Virtual MeetingZynerba Pharmaceuticals Announces the Acceptance of Two Posters at the Society of Biological Psychiatry 2021 Virtual Meeting
finance.yahoo.com - April 15 at 8:38 AM
Zynerba Pharmaceuticals, Inc. (ZYNE) investors to reap big returns againZynerba Pharmaceuticals, Inc. (ZYNE) investors to reap big returns again
marketingsentinel.com - April 13 at 8:39 AM
Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Receives Consensus Rating of "Buy" from BrokeragesZynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Receives Consensus Rating of "Buy" from Brokerages
americanbankingnews.com - April 9 at 8:44 AM
Zynerba Pharmaceuticals to Present at the Needham Virtual Healthcare ConferenceZynerba Pharmaceuticals to Present at the Needham Virtual Healthcare Conference
finance.yahoo.com - April 6 at 7:51 AM
-$0.25 Earnings Per Share Expected for Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) This Quarter-$0.25 Earnings Per Share Expected for Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) This Quarter
americanbankingnews.com - April 6 at 4:10 AM
Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE): The Stock for Success Over the Next Few MonthsZynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE): The Stock for Success Over the Next Few Months
marketingsentinel.com - March 29 at 3:39 PM
Zynerba (ZYNE) Alert: Shareholder Class Action...Zynerba (ZYNE) Alert: Shareholder Class Action...
benzinga.com - March 28 at 1:28 PM
Zynerba (ZYNE) Alert: Shareholder Class Action Survives Motion to Dismiss; Should Management be Held Accountable for Investors Losses? Contact Johnson FistelZynerba (ZYNE) Alert: Shareholder Class Action Survives Motion to Dismiss; Should Management be Held Accountable for Investors Losses? Contact Johnson Fistel
finance.yahoo.com - March 28 at 8:28 AM
Are Investors Keen On Selling Holdings In Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE)?Are Investors Keen On Selling Holdings In Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE)?
stocksregister.com - March 26 at 2:26 PM
Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?
finance.yahoo.com - March 12 at 1:13 PM
Zynerba: Q4 Earnings Snapshot | Raleigh News & ObserverZynerba: Q4 Earnings Snapshot | Raleigh News & Observer
newsobserver.com - March 10 at 1:27 PM
Zynerba: Q4 Earnings SnapshotZynerba: Q4 Earnings Snapshot
thetelegraph.com - March 10 at 8:26 AM
Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational HighlightsZynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
finance.yahoo.com - March 10 at 8:26 AM
CBD Co. Zynerba, Investors Aim To Settle Drug Trial ClaimsCBD Co. Zynerba, Investors Aim To Settle Drug Trial Claims
law360.com - March 10 at 12:33 AM
Global Fibromyalgia Drugs Market Assessment 2021-2026 - Impact of COVID-19, Case Study Analysis, Key Opportunities and Major PlayersGlobal Fibromyalgia Drugs Market Assessment 2021-2026 - Impact of COVID-19, Case Study Analysis, Key Opportunities and Major Players
marketwatch.com - March 5 at 2:35 PM
Zynerba Pharmaceuticals to Participate in the 33rd Annual ROTH ConferenceZynerba Pharmaceuticals to Participate in the 33rd Annual ROTH Conference
finance.yahoo.com - March 4 at 12:40 PM
4 Penny Stocks to Watch in March If You Like Biotech, Are They A Buy?4 Penny Stocks to Watch in March If You Like Biotech, Are They A Buy?
marketwatch.com - March 3 at 5:14 AM
Marijuana as medicine: the other cannabinoid pharma playersMarijuana as medicine: the other cannabinoid pharma players
seekingalpha.com - February 8 at 8:36 AM
ZYNE Stock Price Increases Over 20%: Why It HappenedZYNE Stock Price Increases Over 20%: Why It Happened
pulse2.com - February 3 at 7:05 PM
GW Pharma Soars To Record High On Jazzs $7.2 Billion Takeover DealGW Pharma Soars To Record High On Jazz's $7.2 Billion Takeover Deal
finance.yahoo.com - February 3 at 2:04 PM
Analysts Offer Insights on Healthcare Companies: and Armata Pharmaceuticals (ARMP)Analysts Offer Insights on Healthcare Companies: and Armata Pharmaceuticals (ARMP)
smarteranalyst.com - February 1 at 8:59 AM
DateCompanyBrokerageAction
4/13/2021OtonomyPiper SandlerBoost Price Target
3/1/2021OtonomyHC WainwrightLower Price Target
11/22/2020OtonomyOppenheimerInitiated Coverage
8/17/2020OtonomyCantor FitzgeraldReiterated Rating
5/29/2020OtonomyCraig HallumInitiated Coverage
3/5/2019OtonomyPiper Jaffray CompaniesReiterated Rating
8/14/2018OtonomySunTrust BanksLower Price Target
1/22/2021Adamis PharmaceuticalsMaxim GroupReiterated Rating
8/24/2020Adamis PharmaceuticalsDawson JamesDowngrade
8/19/2020Adamis PharmaceuticalsRaymond JamesReiterated Rating
7/23/2019Adamis PharmaceuticalsB. RileyUpgrade
2/15/2021Anixa BiosciencesAegisReiterated Rating
9/11/2020Minerva NeurosciencesWilliam BlairReiterated Rating
7/1/2020Minerva NeurosciencesJMP SecuritiesReiterated Rating
6/1/2020Minerva NeurosciencesBTIG ResearchLower Price Target
5/29/2020Minerva NeurosciencesJefferies Financial GroupDowngrade
12/2/2019Minerva NeurosciencesChardan CapitalReiterated Rating
8/3/2018Minerva NeurosciencesCitigroupBoost Price Target
3/10/2021Zynerba PharmaceuticalsRoth CapitalLower Price Target
2/5/2021Zynerba PharmaceuticalsCanaccord GenuityReiterated Rating
9/14/2020Zynerba PharmaceuticalsNeedham & Company LLCReiterated Rating
6/29/2020Zynerba PharmaceuticalsLADENBURG THALM/SH SHReiterated Rating
(Data available from 4/22/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.